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Introduction
Glioblastoma multiforme (GBM) is the most common and 
lethal cancer of the adult central nervous system. GBM cells 
uniformly acquire resistance to alkylating agents and to other 
antineoplastic treatments.1 This resistance is associated with 
the upregulation of adenosine triphosphate–binding cassette 
drug efflux pumps.2 MicroRNAs (miRs) can regulate a num-
ber of processes in GBM cells, such as chemoresistance and 
functional drug efflux.3
The miRs are small oligonucleotides, 18–22 base pairs 
long, which regulate gene expression.4 They bind to the 
3′- and 5′-untranslated regions of the targeted mRNAs 
to suppress translation. The functioning of miRs does not 
require complete complementarity. Furthermore, miRs have 
major, but parallel, roles in cell differentiation and oncogenic 
transformation.5 Through the targeting of specific genes, 
miRs can behave functionally as tumor suppressors or 
oncogenes.6
miRs are upregulated in glioma cells and are involved in 
developmental processes.7 Among these are miR-9 mol-
ecules that have been shown to suppress mesenchymal dif-
ferentiation of GBM cells.7 This report investigated the role of 
miR-9 in the resistance of GBM cells to temozolomide (TMZ). 
P-glycoprotein (P-gp) is involved in the chemoresistance of 
GBMs.8 Furthermore, miR-9, through an indirect method, 
affected the increase in P-gp (unpublished data). This study 
assesses the feasibility of using anti-miR as a treatment to 
reverse the expression of P-gp and to sensitize otherwise-
resistant GBMs to TMZ.
miR-targeting therapeutics in GBM is an area of extensive 
research.9 Yet, functional delivery of these targeted treat-
ments without the use of viral vectors is yet to be successful. 
Cell-based delivery mechanisms have become an attractive 
method for delivering miR and anti-miR for therapies, particu-
larly through stem cells, due to their tropism to the region of 
GBM cells.10 Neural stem cells and mesenchymal stem cells 
(MSCs) are currently in trials as drug delivery modes for 
GBM.11 Although neural stem cells have been shown to be 
effective in drug delivery, the challenges of harvesting, expan-
sion, and their immunogenic ability have limited their applica-
tion in humans.12 By contrast, MSCs, which are efficient in the 
delivery of drugs in cancer treatment, have added advantages 
in terms of ease of expansion, harvesting, and the ability to 
be transplanted into allogeneic host as ‘off-the-shelf’ cells.13
MSCs can communicate with cancer cells through gap 
junctional intercellular communication (GJIC) and also 
through secreted exosomes.14,15 In this report, we show 
reversed chemoresistance of GBM cells to TMZ. We showed 
that this occurred by targeting of anti-miR through MSCs. In 
addition, we showed a significant role of MSC-derived exo-
somes in the transfer of anti-miR-9 compared with the GJIC 
between MSCs and GBM cells.
Results
The purpose of the study is to determine whether MSCs 
can be used for providing treatment to GBMs. In addition, 
the plan is to determine whether delivery can occur through 
direct contact using the GJIC or indirectly through vesicles. 
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Glioblastoma multiforme (GBM), the most common and lethal tumor of the adult brain, generally shows chemo- and 
radioresistance. MicroRNAs (miRs) regulate physiological processes, such as resistance of GBM cells to temozolomide (TMZ). 
Although miRs are attractive targets for cancer therapeutics, the effectiveness of this approach requires targeted delivery. 
Mesenchymal stem cells (MSCs) can migrate to the sites of cancers, including GBM. We report on an increase in miR-9 in 
TMZ-resistant GBM cells. miR-9 was involved in the expression of the drug efflux transporter, P-glycoprotein. To block miR-9, 
methods were developed with Cy5-tagged anti-miR-9. Dye-transfer studies indicated intracellular communication between GBM 
cells and MSCs. This occurred by gap junctional intercellular communication and the release of microvesicles. In both cases, 
anti-miR-9 was transferred from MSCs to GBM cells. However, the major form of transfer occurred with the microvesicles. The 
delivery of anti-miR-9 to the resistant GBM cells reversed the expression of the multidrug transporter and sensitized the GBM 
cells to TMZ, as shown by increased cell death and caspase activity. The data showed a potential role for MSCs in the functional 
delivery of synthetic anti-miR-9 to reverse the chemoresistance of GBM cells.
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Anti-miR was used for testing the effectiveness of the deliv-
ery method.
Characterization of MSCs
Although MSCs can be isolated from a number of tissues and 
locations, the phenotypes are mostly uniform.16 We showed 
the phenotypes of CD44, CD45, and CD105 and their multi-
lineage capacity. Flow cytometric analyses indicated consis-
tent expression of CD44 and CD105 and undetectable CD45, 
indicating nonhematopoietic bone marrow–derived cells 
(Figure 1a). Bright-field images of cultured MSCs indicated 
symmetrically shaped, fibroblastoid cells consistent with the 
characteristics of MSCs (Figure 1b; left panel).17 The two lin-
eages studied indicated efficient adipogenic and osteogenic 
differentiation, confirming the multipotency of the experimen-
tal MSCs (Figure 1b).
Intercellular communication between MSCs and GBM 
cells
MSCs can have intercellular communication with other cell 
types.18 These cells can communicate with GBMs through 
direct contact by GJIC and/or by contact-independent 
method. The latter entails communication through soluble 
factors and/or the secretion of vesicles. The two methods 
(Figure 2a) are shown as transwell cultures for contact-inde-
pendent communication and as cocultures for direct intercel-
lular communication (GJIC).
MSCs were labeled with the fluorescent CellTracker 
Orange (CMTMR ([5-(and-6)-(((4-chloromethyl)benzoyl)
amino) tetramethyl-rhodamine]); Figure 2b) in both the cul-
tures. In the contact-dependent method (cocultures), the 
GBM cells (U87 and T98G) were unlabeled. The transfer of 
CMTMR was studied using flow cytometry. After 72 hours, 
>85% of the dye was transferred to the GBM cells (Figure 2c; 
left panels versus middle panels).
The contact-independent (transwell) cultures, which con-
tained upper and lower chambers, were separated by 0.4-
µm membranes (Figure 2a; left panel). The labeled MSCs 
were placed in the upper chambers and the unlabeled GBM 
cells were placed in the lower chambers. The MSCs could not 
migrate through the membranes. Unlike the cocultures, only 
~16% of the dye was transferred from the MSCs to the GBM 
cells (Figure 2c; left panels versus right panels).
Intracellular CMTMR cannot be passively secreted from 
the MSCs to enter the GBM. Furthermore, the MSCs were 
>99% viable, thereby eliminating the release of CMTMR from 
nonviable MSCs. Therefore, the 16% dye transfer could occur 
only through MSC-derived vesicles. Thus, we showed inter-
cellular communication between MSCs and GBM cells by 
two different mechanisms.
Transfer of anti-miR-9 from MSCs to GBM cells through 
the GJIC
The literature indicated that small oligonucleotides, such as 
miRs, can be shuttled from one cell type to another through 
connexin-dependent GJIC.19 miR-9 has been shown to be 
involved in neural development.20 Because GBM cells gener-
ally reactivate neural developmental pathways,21 we asked 
whether miR-9 was increased in GBM cells. If so, we would 
be able to take advantage of the intercellular communication 
between MSCs and GBM cells to target the miR-9.
We proposed that the resistant GBM cells will express miR-
9. We therefore treated U87 and T98G with 200 µMol/l TMZ 
or vehicle. After 72 hours, the viable/resistant GBM cells were 
studied to know the miR-9 levels using real-time polymerase 
chain reaction (PCR). The values in the untreated cells were 
normalized to 1 and then used as the basis to calculate fold 
change in the TMZ-resistant GBM cells. The results indicated 
a significant (P < 0.05) increase in the miR-9 levels of TMZ-
treated GBM cells (Figure 3a).
Figure 1  Characterization of mesenchymal stem cells (MSCs). (a) Bone marrow–derived MSCs were analyzed by flow cytometry for 
CD45, CD44, and CD105 or (b) subjected to lineage differentiation. Left images show passage 5 MSCs at original magnification ×100.
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We next asked whether miR-9 can be blocked with anti-
miR-9 and whether the anti-miR can be delivered through 
GJIC to the GBM cells. First, we investigated whether anti-
miR can pass from MSCs to the GBM cells (T98G and U87) 
through the GJIC. To address this question, we synthesized 
anti-miR-9 tagged with Cy5. To identify the GBM cells, we 
labeled them with carboxyfluorescein diacetate (CFDA), 
which was not significantly transferred to the MSCs during 
the 72-hour incubation period (Figure 3b).
The transfer of Cy-5-anti-miR-9 was studied using flow 
cytometry. This was indicated by the detection of Cy5 in the 
CFDA-labeled GBM cells. As expected, no Cy5 was detected 
in the U87 and T98G cultured alone (Figure 3c,d; left pan-
els). However, after coculture, the CFDA(+) GBM cells were 
also positive for Cy5 (Figure 3c,d; middle panels), indicating 
that anti-miR-9-Cy5 was transferred from the MSCs to the 
GBM cells. Histograms for Cy5 in the CFDA (+) GBM cells 
are shown in Figure 3c,d (right panels).
Because dye can be transferred from MSCs by a method 
other than GJIC (Figure 2), we asked whether the transfer of 
Cy-4-anti-miR-9 from the MSCs to the GBM cells occurred 
through GJIC. First, we asked whether connexin 43 (Cx43), 
which forms the GJIC, was present in cocultures of MSCs and 
GBM cells. Immunocytochemistry resulted in bright labeling 
for Cx43 between the MSCs and the GBM cells (Figure 3e). 
We next performed cocultures in the presence of the GJIC 
blocker 300 µMol/l 1-octanol.22 The control contained vehicle. 
The addition of 1-octanol resulted in 5–10% decrease in Cy5 
fluorescence in the GBM cells (Figure 3f), indicating that 
there are also other mechanisms involved in the transfer of 
anti-miR-9-Cy5 to GBM cells. Due to the small decrease in 
the GJIC, we performed a control study with breast cancer 
cells, which can form GJIC at confluence.23 Indeed, the pres-
ence of 1-octanol blocked the transfer of dye (Supplemen-
tary Figure S1). Taken together, these experiments indicated 
intracellular communication between the MSCs and the GBM 
cells and also suggested that other mechanisms of commu-
nication exist independent of the GJIC.
Contact-independent transfer of anti-miR-9-Cy5 from 
MSCs to GBM cells
Communication between cells may be contact dependent 
(GJIC) or contact independent (vesicular secretion). Figure 3 
shows that many methods of communication other than GJIC 
may exist between MSCs and GBM cells. We therefore stud-
ied whether anti-miR-9-Cy5 was transferred from MSCs to 
Figure 2  Intercellular communication between mesenchymal stem cells (MSCs) and glioblastoma multiforme (GBM) cells. (a) The 
figure depicts the contact-independent transwell cultures and contact-dependent cocultures. (b) The cell tracker dye, CMTMR, was used 
to follow intercellular communication. The efficiency of loading CMTMR in MSCs is shown. (c) Flow cytometry for CMTMR in GBM cells in 
cocultures and transwell studies. CMTMR, [5-(and-6)-(((4-chloromethyl)benzoyl)amino) tetramethyl-rhodamine].
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the GBM cells in the transwell cultures (Figure 2a; left panel). 
We placed anti-mir-9-Cy5-transfected MSCs in the upper 
chamber and 5-chloromethyl fluorescein diacetate (CMFDA)-
labeled U87 and T98G cells in the lower chamber. After 72 
hours, the GBM cells were collected and then analyzed by 
flow cytometry, as shown in Figure 3. The GBM cells cultured 
alone were negative for Cy5 (Figure 4a,b; left panels). How-
ever, GBM cells in transwell cultures with the transfected 
MSCs showed Cy5 fluorescence in the CFDA(+) GBM cells 
(Figure 4a,b; middle panels). The histogram of Cy5 fluores-
cence from the transwell cultures is shown in Figure 4a,b 
(right panels). As the anti-miR-Cy5 can only enter the GBM 
Figure 3  Transfer of anti-miR-9-Cy5 from mesenchymal stem cells (MSCs) to glioblastoma multiforme (GBM) cells. (a) Real-time 
polymerase chain reaction for miR-9 in U87 and T98G, untreated and treated with 200 µMol/l temozolomide (TMZ). The data for the TMZ-
treated cells are presented as fold change in relation to vehicle, which is normalized to 1. (b) GBM cells were labeled with the cell tracker 
CMFDA and then placed in contact with MSCs. After 72 hours, the cells were analyzed for changes in Cy5. (c,d) Cocultures or transwell 
studies with anti-miR-9-Cy5-transfected MSCs and (c) CMFDA-loaded U87 or (d) T98G were studied for the transfer of Cy5 probe. Left panels 
show the GBM cells alone; middle panels analyze the GBM cells for CMFDA and Cy5; right panels show Cy5 alone in the GBM cells. (e) 
Representative immunocytochemistry is shown for Cx43 in cocultures of MSCs and U87 or T98G cells. The arrows show Cx43 (green) between 
two cells. Immediately before examining the cells, the cultures were labeled with phalloidin and diamidino-2-phenylindole. (f) Cocultures of U87 
or T98G and MSCs were studied in the presence or absence of 300 µMol/l 1-octanol. After 72 hours, the cells were studied for Cy5.
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cells by vesicular transfer, the data suggest this type of trans-
fer from MSCs to the GBM cells.
We performed studies to verify that anti-miR-9 was 
transferred by microvesicles. We repeated the transwell 
cultures in Figure 2, except that we blocked the release of 
microvesicles using 2.5 µMol/l manumycin A (neutral sphin-
gomyelinase 2, nSMase2).24 Thus, the transwell cultures 
were established, as shown in Figure 2a, in the presence 
Figure 4  Exosomal transport of anti-miR-9-Cy5 from mesenchymal stem cells (MSCs) to glioblastoma multiforme (GBM) cells. (a,b) 
GBM cells were labeled with the cell tracker CMFDA and then placed in the lower chambers of a transwell system. Anti-miR-9-Cy5-transfected 
MSCs were placed in the upper chamber of the transwell. After 72 hours, the cells were analyzed for changes in Cy5. Left panels show the 
GBM cells alone; middle panels analyze the GBM cells for CMFDA and Cy5; right panels show Cy5 alone in the GBM cells. (c) Cocultures of 
U87 or T98G and MSCs were studied in the presence or absence of 300 µMol/l 1-octanol. After 72 hours, the cells were studied for Cy5. (d) 
Exosomal miR-9 from GBM cells was analyzed for miR-9 levels using real-time polymerase chain reaction. (e,f) MSCs were (e) transfected 
with anti-miR-Cy5 and then (f) characterized by western blot. (g) MSC-derived exosomes were added to GBM cells, and after 24 hours, the 
cells were examined for Cy5 by flow cytometry.
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or absence of manumycin A. The presence of manumy-
cin A in the cultures reduced the fluorescence intensities 
(Figure 4c; open histograms) compared with the cultures 
without manumycin A (Figure 4c; solid histograms). The 
findings indicated that vesicular secretion was important for 
the transfer of anti-miR-Cy5 from MSCs to the GBM cells.
Exosome-containing miR-9 from TMZ-resistant GBM 
cells
Figure 4a–c supports the role of vesicles in the transfer of 
anti-miR-9 from MSCs to GBM cells. We therefore extrapo-
lated the findings to investigate how resistant GBM cells can 
sustain similar effects on neighboring GBM cells. To address 
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this, we collected exosomes from GBM cells, either untreated 
or treated with 200 µMol/l TMZ for 72 hours, and then stud-
ied the miR-9 levels using real-time PCR. TMZ treatment 
showed a twofold increase in exosomal miR-9 in the resistant 
U87 and T98G cells (Figure 4d). These findings indicated 
that chemoresistance could be influenced in the GBM cells 
through the release of miR-9-containing exosomes.
The increase in miR-9 in the exosomes of TMZ-treated 
cells could be caused by endogenous increase or by 
increase in the amount of secreted exosomes. To discrimi-
nate which method occurred, we collected exosomes from 
GBM cells, which were (i) either untransfected or with ectopic 
expression of miR-9 and (ii) untreated or treated with 200 
µMol/l TMZ. The exosomes were studied for miR-9 levels 
using real-time PCR. The values in the untreated cells were 
normalized to 1, and the TMZ-treated cells were expressed 
as fold change. The results indicated significant (P < 0.05) 
increase in miR-9 in relation to nontransfected, TMZ-treated 
GBM cells   (Figure 4d). These findings indicated an increase 
in exosomal miR-9 by TMZ treatment. The findings in 
  Figure 4d show that, in addition to anincrease in miR-9 levels 
 (Figure 3a), TMZ also increased vesicular secretion.
Direct transfer of exosomes from MSCs to GBM cells
The data in Figure 4a–d indicate that anti-miRs have the 
potential for therapy if they can be transferred by exosomes 
to GBM cells. We therefore investigated whether anti-miR-con-
taining exosomes from MSCs can be transferred directly into 
GBM cells. We labeled MSCs with anti-miR-Cy5 (Figure 4e) 
and then collected exosomes from these MSCs. The exo-
somes were characterized using specific markers by western 
blotting (Figure 1f).25 We added the MSC-derived exosomes 
to the GBM cells. As the exosomes were collected from anti-
miR-Cy5-transfected MSCs, if the exosomes entered the GBM 
cells, this would be indicated by Cy5 fluorescence. Indeed, flow 
cytometry showed an increase in Cy5 (Figure 4g). A direct 
transfer of MSC-derived exosomes into GBM cells is thus 
possible.
Anti-miR-9 reversed MDR1 expression in TMZ-resistant 
GBM cells
Drug transporters are expected to be increased in TMZ-
resistant GBM cells. We therefore asked whether an increase 
in miR-9 is important for the chemoresistance of GBM cells 
(Figure 3a). If so, inhibiting miR-9 with anti-miR is expected 
to decrease the expression of the drug transporter gene, 
MDR1, resulting in reversal of TMZ resistance. First, we 
studied the functionality of the anti-miR-9-Cy5 by determin-
ing whether it can reduce the miR-9 level. We treated anti-
miR-9-Cy5-transfected GBM cells with 200 µMol/l TMZ for 72 
hours and then studied the levels of miR-9 using real-time 
PCR. Control cultures were treated with vehicle and were 
untransfected with anti-miR-Cy5. The untransfected/TMZ-
treated cells showed approximately sixfold increase in miR-9 
compared with the vehicle-treated ones (Figure 5a, diago-
nal bars). By contrast, anti-miR-9-Cy5 transfectants showed 
50% decrease in miR-9 (Figure 5a, hatched bars), indicating 
that the anti-miR-9-Cy5 was able to functionally interact with 
miR-9 to decrease its level.
We next determined whether intercellular communication 
between MSCs and GBM cells (Figures 2 and 3) can be 
applied as a potential therapy. The goal was to determine 
whether the effect of miR-9 can be reversed with anti-miR-
containing MSCs. If miR-9 is important for drug resistance, 
anti-miR-9 will reverse TMZ resistance and decrease MDR1 
expression. We performed cocultures with MSCs and GBM 
cells. The MSCs were transfected with anti-miR-9-Cy5, and 
the GBM cells were labeled with CFDA for the purpose of 
discriminating between the two cell types (Figure 3). The 
cocultures were treated with vehicle or 200 µMol/l TMZ in the 
presence or absence of 300 µMol/l 1-octanol to block GJIC. 
After 72 hours, the cells were analyzed for surface P-gp (the 
MDR1 gene product). TMZ-treated cells showed five- to six-
fold more P-gp compared with untreated cells (Figure 5b). 
Parallel cocultures with 1-octanol resulted in minimum 
change in P-gp expression (Figure 5c). Because 1-octanol 
prevents the transfer of anti-miR-9-Cy5, the anti-miR was 
probably transferred by a method independent of GJIC. We 
therefore exposed the cocultures to 2.5 µMol/l manumycin 
A, which prevented vesicular release. Flow cytometry for 
P-gp showed a decrease in the mean fluorescence intensity 
(Figure 5d, shift from open histogram to solid histogram). 
The effect of manumycin A indicated that the transfer of anti-
miR-9 occurred by vesicular transfer (Figure 4). Thus, anti-
miR-9-Cy5 was functional and was transferred from MSCs 
to GBM cells, mostly through microvesicles. The transfer 
blocked the increase in P-gp.
Knockdown of P-gp in TMZ-resistant cells conferred 
apoptosis
Figure 5a,b shows the link between miR-9 and the expres-
sion of MDR1. To determine whether MDR1 expression 
Figure 5  Anti-miR-9-Cy5 reversed glioblastoma multiforme (GBM) chemoresistance. (a) Real-time polymerase chain reaction (Taqman) 
was performed with RNA extracted from GBM cells (T98G and U87). The cells were transfected with anti-miR-9-Cy5 and then treated with 
200 µMol/l temozolomide (TMZ) or vehicle for 72 hours. (b) GBM cells were untreated or treated with TMZ as for “a.” The surviving resistant 
cells were labeled with CFDA dye, then cocultured with MSCs, and transfected with anti-miR-9-Cy5. After 72 hours, the cells were analyzed 
by flow cytometry for surface P-glycoprotein (p-gp; MDR1). (c) TMZ-resistant T98G and U87 were established as cocultures with MSCs as 
for “b,” in the presence or absence of 1-octanol. After 72 hours, the cells were analyzed for P-gp expression. (d) The cocultures in “c” were 
repeated, except in the presence or absence of manumycin. After 72 hours, the cells were analyzed by flow cytometry for P-gp. (e) U87 and 
T98G cells were stably knocked down for MDR1 or a nontargeting vector (control). The transfectants were treated with 200 µMol/l TMZ. After 
72 hours, the cells were analyzed for caspase 3/7 activity by flow cytometry using the Vybrant(R) FAM Caspase 3/7 Assay kit. Solid histogram: 
control; open histogram: MDR1 knockdown. (f) Low-passage patient-derived cell lines (BT145, TMZ sensitive; BT164, TMZ resistant) are 
shown as nonadherent neurospheres. (g) Western blot was performed for P-gp using whole-cell extracts with the low-passage cell lines. (h) 
BT164 cells were transfected with anti-miR-9-cy5 and then analyzed for P-gp by western blot. (i) BT145 and BT164 cells were transfected 
with anti-miR-9-Cy5 or nontargeting anti-miR. The transfectants were treated with TMZ. After 72 hours, the cells were analyzed for viability 
using CellTiter–Blue assay. The viability with vehicle was normalized to 100% and then used as the base to calculate the percent change for 
the other experimental points; results are presented as mean ± SD, n = 4. *P < 0.05 versus vehicle.Molecular Therapy—Nucleic Acids
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is secondary to miR-9 for sensitivity to TMZ, we knocked 
down  MDR1 with short hairpin RNA (shRNA) and then 
studied whether this affected the sensitivity of GBM cells 
to TMZ. Controls were transfected with a nontargeting 
shRNA. The transfectants were treated with 200 µMol/l 
TMZ, and after 72 hours, the cells were analyzed for cas-
pase-3/7. The results showed a shift in the positive direc-
tion, indicating increased apoptosis by the TMZ-treated 
cells (Figure 5e).
miR-9 in the sensitivity of low-passage GBM cells
The studies described above used established GBM 
cell lines. We asked whether the findings on miR-9 as a 
mediator of GBM resistance also occurred in low-passage 
GBM cells. We addressed this question with two low-pas-
sage cell lines from patients: recurrent GBM that resisted 
TMZ (BT164 cells) and a cell line from a naive patient 
(BT145 cells). We first studied the expression of P-gp and 
observed an increase in the band in BT164 (Figure 5g). 
The P-gp band was significantly reduced when BT164 
was transfected with anti-miR-9 (Figure 5h), indicating 
that miR-9 was responsible for the increase in P-gp. The 
decrease in P-gp with anti-miR also sensitized BT164 to 
TMZ   (Figure 5i). The naive BT145 cells showed signifi-
cant (P < 0.05) cell death, regardless of transfection status 
 (Figure 5i). In summary, the role of miR-9 in TMZ resis-
tance was also noted for a low-passage recurrent GBM cell 
line from a patient.
Figure 6 Anti-miR-9 treatment enhanced temozolomide (TMZ)-induced cell death. (a) Cell viability assay was performed with 
glioblastoma multiforme (GBM) cells treated with 200 µMol/l TMZ. The cells were transfected with anti-miR-9-Cy5 or nontargeted 
oligonucleotides. Adenosine triphosphate content was assayed by CellTiter-Blue assay. The data are presented as percentage cell viability ± 
SD, n = 12. (b) Caspase-3 activity (caspase-3 cleavage) was studied by western blot (upper panel). The normalized band densities are shown 
in the lower graphs.*P < 0.05 versus TMZ treatment alone.
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MSC-derived anti-miR-9 conferred sensitivity to TMZ on 
GBM cells
Because anti-miR-9 decreased the expression of MDR1 
(Figure 5), we asked whether anti-miR-9 can sensitize GBM 
cells to TMZ. U87 and T98G cells were transfected with 15 
and 30  nM anti-miR-9-Cy5, respectively, and then treated 
with vehicle or 200 µMol/l TMZ. After 72 hours, cell viabil-
ity was assessed with the CellTiter-Blue kit, and caspase 
activity was studied using western blotting. Cell viability was 
significantly (P < 0.05) decreased with anti-miR-9-Cy5 treat-
ment compared with TMZ treatment alone (Figure 6a).
Western blot analyses for uncleaved (35  kDa) and cleaved 
caspase-3 (17  kDa) showed an increase in the latter when 
the anti-miR-9-Cy5 transfectants were treated with TMZ 
 (Figure 6b). The normalized band densities are shown in the 
lower graphs of Figure 6b. Altogether, the results indicated that 
anti-miR-9 increased active caspase and concomitantly caused 
enhanced cell death in response to TMZ treatment alone.
Discussion
Refractoriness of GBM cells to chemotherapy and enhanced 
tumor growth commonly occur in GBM cells.26 Several studies 
and clinical trials have used stem cells for delivering drugs to 
the sites of GBMs. These include current experimental thera-
peutics to deliver targeted prodrugs or genes. Human MSCs 
have been shown to exhibit tropism for the site of GBM. The 
chemoattraction of MSCs has been shown to depend on a 
number of chemokines and other cytokines, such as inter-
leukin-1 and stromal derived factor-1 (SDF-1/CXCR4). In this 
article, we report on a potential RNA therapy for the neuro-
developmental miR-9 through the delivery of MSCs to make 
GBMs sensitive to TMZ.
We used human bone marrow–derived MSCs with anti-
miR tagged with Cy5 to show effective transfer of the anti-miR 
from MSCs to GBM cells. This occurred through contact-
dependent (GJIC) and contact-independent mechanisms 
(Figures 3 and 4). Because transfected MSCs remained 
viable, the Cy5 could not be derived from nonviable cells 
but could only be derived through regulated transfer. We 
showed a role for secreted exosomes in the communication 
between MSCs and GBM cells (Figures 4 and 5). The MSCs 
were multipotent and expressed Cx43 (Figures 1 and 3d). 
We used Cy5-tagged anti-miR-9 for tracking the transfer of 
the molecules. We demonstrated that the anti-miR-9 could 
decrease miR-9 and also reduce the resistance of GBMs to 
TMZ (Figure 6). This increased sensitivity of the anti-miR-
9-containing GBMs correlated with the expression of the drug 
transporter P-gp (MDR1; Figure 5). The use of transwell cul-
tures and flow cytometric analyses indicated that the ability of 
anti-miR-9 to make the cells chemosensitive could be applied 
by delivering the anti-miR through MSCs. The transfer was 
seen to be primarily through exosome-dependent intracellu-
lar communication rather than GJIC (Figure 5). This is a sig-
nificant finding because the release of exosomes would be 
able to affect GBM cells that are at a considerable distance 
from the MSCs.
Anti-miR-9 delivered to the TMZ-resistant GBM cells was 
able to reduce the endogenous upregulation of miR-9 in 
response to TMZ, in addition to significantly reducing cell sur-
face P-gp. This protein is the product of the drug transporter 
MDR1, which is commonly associated with chemoresistance 
of cancer cells (Figure 5). Furthermore, we assessed the 
effects of anti-miR-9-Cy5 in the sensitization of GBM cells 
to TMZ. We transfected GBM cells with anti-miR-9-Cy5 and 
treated them with TMZ for 72 hours. Cell death was measured 
by adenosine triphosphate content (CellTiter–Blue assay) 
and caspase activity (western blot). The results indicated an 
enhancement of cell death when the anti-miR-9-Cy5 was 
combined with TMZ compared with the level of cell death with 
TMZ alone (Figure 6).
The field of RNA therapeutics has yet to identify a specific-
target approach to GBM by anti-miR delivery. In this report, 
we showed the feasibility and the effectiveness of MSC-tar-
geted delivery of anti-miR for GBM chemoresistance. The 
innate tropism of MSCs for GBMs and the ability of alloge-
neic MSCs to be used as off-the-shelf stem cells make the 
findings exciting because the method has potential for use 
in therapy.
Materials and methods
Reagents.  All tissue culture media were purchased from 
Gibco (Grand Island, NY); fetal calf serum was from Hyclone 
Laboratories (Logan, UT); TMZ, 1-octanol, and manumycin A 
were from Sigma Aldrich (St. Louis, MO), and lipofectamine 
RNAiMax was from Invitrogen (Grand Island, NY). Anti-
microRNA-9-Cy5 (5′-Cy5-TCA TAC AGC TAG ATA ACC AAA 
G-3′) was synthesized by Sigma Aldrich.
Murine anti-human P-gp (UIC2 clone)-PE was purchased 
from Biolegend (San Diego, CA); anti-CD45-PE, anti-CD44-
APC, and anti-CD45-V450 from BD Biosciences (San Jose, 
CA); and anti-caspase 3 from Cell Signaling (Danvers, MA).
Cells. U87 and T98G cells were purchased from American 
Type Culture Collection (Manassas, VA) and then grown as 
per manufacturer’s instructions. As of 2007, histopathological 
analyses of both cell lines confirmed the diagnosis of Astro-
cytoma grade 4 (GBM).
BT145 (primary GBM) and BT164 (recurrent GBM) gli-
oma cell lines were derived from surgical resection material 
acquired from patients undergoing surgery at the Brigham 
and Women’s Hospital on an Institutional Review Board-
approved protocol as part of the DF/BWCC Living Tissue 
Bank. Briefly, tumor resection samples were mechanically 
dissociated and tumor spheres were established and propa-
gated in Human NeuroCult NS-A Basal medium (StemCell 
Technologies) supplemented with epithelial growth factor,   
fibroblast growth factor, and heparin sulfate.
Culture of human MSCs. The use of human bone marrow 
aspirates followed a protocol approved by the Institutional 
Review Board of UMDNJ-Newark Campus. All subjects 
signed an informed consent. The ages of donors ranged 
between 18 and 35 years. MSCs were cultured from the aspi-
rates as previously described.17 Briefly, unfractionated bone 
marrow aspirates were diluted in Dulbecco’s modified eagle 
medium (Invitrogen,   Carlsbad, CA) containing 10% fetal calf Molecular Therapy—Nucleic Acids
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serum (Hyclone, Logan, UT) and then seeded in plasma-
treated Falcon 3003 Petri dishes. The plates were incubated 
at 37 °C. On day 3, the mononuclear cells were selected 
by Ficoll Hypaque (Sigma, St Louis, MO) density gradient 
centrifugation and then replated on the culture plates. Fifty 
percent of the media were replaced with fresh media. At 
80% confluence, the adherent cells were subjected to serial 
passages. At passage 5, the cells were CD45(−), CD14(−), 
CD44(+), CD29(+), CD105(+), and CD34(−).
Mesodermal differentiation. Adipogenic and osteogenic 
induction of MSCs was performed using Poietics Human Mes-
enchymal Stem Cells kit (Lonza, Switzerland). Briefly, MSCs 
were seeded in complete medium at a density of 2  ×  104/
cm2 on plates treated with vacuum–gas plasma. Cells were 
allowed to adhere for 24 hours. The media were replaced at 
72-hour intervals until confluence. The MSCs were induced as 
per manufacturers’ instructions. Adipocyte staining was done 
using cells fixed in 10% formalin by incubation with 0.18% Oil 
Red O (Sigma) solution for 5 minutes. Osteogenic induction 
was based on mineralization of the bone. The induced cells 
were observed by bright-field microscopy at ×100.
Dye-transfer assay. For this assay, 5 × 105 cells were seeded 
in a 12-well plate. At adherence, 2.5 µMol/l of prewarmed 
CellTracker Orange CMTMR (Molecular Probes, Grand 
Island, NY) or CellTracker Green CMFDA (Molecular Probes) 
was added to the medium. The cells were incubated for 45 
minutes at 37 °C in a CO2 incubator. The cells were washed 
with phosphate-buffered saline (PBS) and then reincubated 
with fresh culture medium. After 6 hours, the cells were 
washed with PBS and cocultured with 5 × 105 unlabeled cells. 
After 72 hours, the cells were trypsinized, harvested by cen-
trifugation, resuspended in 0.5  ml of PBS, and then imme-
diately evaluated by flow cytometry using a BD LSR II (BD 
Biosciences).
MSCs labeled with CMTMR were either cultured at 1:3 
ratio with GBM cells for contact-dependent dye transfer or 
cultured in the upper chamber of a 0.4-µm transwell culture 
system with CMFDA+ GBM cells in the lower chamber. Both 
culture methods spanned 72 hours.
Real-time reverse transcriptase-PCR.  RNA was extracted 
using Trizol reagent (Invitrogen). Reverse transcription was 
performed with 200  ng of cDNA using Taqman MicroRNA 
Reverse Transcription Kit (Applied Biosystems, Foster City, CA) 
in accordance with the manufacturer’s recommendation. Real-
time PCR was performed on the 7300 Real-Time PCR System 
(Applied Biosystems) using the following parameters: an initial 
incubation of 50 °C for 2 minutes, followed by incubation at 
95 °C for 10 minutes. The cycling conditions were as follows: 
95 °C for 15 seconds and 60 °C for 60 seconds, for 40 cycles. 
Taqman miRNA expression kit was purchased from Applied 
Biosystems. miR expression was normalized with RNU6B 
expression. The relative expression was calculated using the 
2(-Delta Delta C(T)) method, as previously described.19
Western blot. Whole-cell extracts were isolated using M-PER 
Mammalian Protein Extraction Reagent (Thermo Scientific, 
Danvers, MA). The extracts (3–7 µg) were analyzed by 
western blots on 12% sodium dodecylsulfate–polyacryl-
amide gel electrophoresis (SDS-PAGE) gels (Bio-Rad, Her-
cules, CA), as described.23 Proteins were transferred onto 
polyvinylidenefluoride membranes (Perkin Elmer, Boston, 
MA). The membranes were incubated overnight with pri-
mary antibodies at final dilutions of 1/500–1/1,000. Primary 
antibodies were detected during a 2-hour incubation period 
with horse radish peroxidase conjugated immunoglobulin 
G at 1/2,000 final dilution. Horse radish peroxidase activ-
ity was detected by chemiluminescence using SuperSignal 
West Femto Maximum Sensitivity Substrate (Thermo Scien-
tific). Membranes were stripped with Restore Stripping Buf-
fer (Thermo Scientific) and then reprobed for other proteins. 
Band density analyses were carried out using the Un-Scan-
It software (Silk Scientific, Orem, UT).
MDR1 knockdown. To assess the importance of MDR1 
expression in GBM resistance to TMZ, U87 and T98G cells 
were transiently transfected with MDR1-RFP-C-RS (Ori-
gene Technologies, Rockville, MD). This vector constitu-
tively expresses MDR1 shRNA and Red Fluorescent Protein 
(RFP). Control GBM cells were transfected with nontarget-
ing shRNA. Stable transfectants were selected by puromy-
cin exposure (0.5 µg/ml). The transfectants were treated with 
200 µMol/l TMZ. At 72 hours, the cells were studied for cas-
pase-3/7 activity using Vybrant FAM Caspase-3/7 Assay Kit 
(Invitrogen). Florescence was analyzed on the BD LSR II, 
after initially gating on RFP-expressing cells.
Cell viability assay. Cells were seeded at 1.5 × 104/well in trip-
licate and then treated with 200 µMol/l TMZ or vehicle. After 
72 hours, cell viability was studied using the CellTiter-Blue 
Cell Viability Assay (Promega, Madison, WI).
Isolation of exosomes. Cell media were depleted of sera con-
taining exosomes by overnight ultracentrifugation at 100,000 
g and then stored at 4 °C. U87 and T98G cells (parental cells 
and cells overexpressing miR-9) were plated at 5  ×  106 per 
flask in standard media. After 24 hours, the cells were washed 
twice with PBS and then cultured with exosome-depleted 
media containing 200 µMol/l TMZ or vehicle. After 72 hours, 
the media were collected and then subjected to differen-
tial ultracentrifugation to isolate exosomes as described.27 
The media were first centrifuged at 2,000 g for 20 minutes 
to remove any live or dead cells. After this, the supernatant 
was transferred to a sterile tube for centrifugation at 10,000 g 
for 30 minutes to remove the remaining cell debris and large 
vesicles. The new supernatant was transferred to ultracentri-
fuge tubes and spun at 100,000 g for 80 minutes. The super-
natant was disposed, and the exosome pellet was washed 
with PBS. A final spin was done at 100,000 g for 80 minutes, 
and the exosome pellet was resuspended in 100 µl PBS. 
RNA was isolated from the exosomes with Trizol according to 
the manufacturer’s instructions.
We also isolated exosomes using the Total Exosome Isola-
tion kit from Invitrogen according to the manufacturer’s proto-
col. The assays used exosome-cleared media, as described 
above, or sera-free media. The latter were used if the cells 
were stimulated for <24 hours. Prolonged experiments used 
exosome-cleared media with fetal calf serum.www.moleculartherapy.org/mtna
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Statistical analyses. Data were analyzed using the paired 
t-test for two comparable groups (control versus experimen-
tal). A P value <0.05 was considered significant.
Supplementary material
Figure S1. Control studies on the effects of 1-octanol on 
GJIC.
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